Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessPfizer's Bourla calls for yearly COVID vaccine shot instead of boosters every...

Pfizer’s Bourla calls for yearly COVID vaccine shot instead of boosters every few months

Add to Favorite
Added to Favorite

On Saturday, Albert Bourla, who is the chief executive officer (CEO) of Pfizer, said that an annual vaccine for COVID-19 rather than frequent booster shots would be preferred. As the cases have soared globally, some countries have expanded the rollout of booster shots while others have shortened the gap between shots; to increase protection.

The booster shot from Pfizer-BioNTech has been successful in decreasing the severity of a Covid infection due to the omicron variant and has prevented deaths. Breakthrough cases are generally mild but the booster shot has not be effective in preventing the transmission of the infection.

Speaking on Israel’s N12 News, the CEO said that he was hoping that Pfizer would have a vaccine that had to be taken once a year. He said that it would be easier to convince people to take a shot. It would also be easier for them to remember to take a shot.

Bourla said that the pharmaceutical giant was looking at a vaccine that covered omicron while it also “doesn’t forget the other variants.” He said that the company was looking for such a solution. He also said that they could be ready with a redesigned vaccine that would battle with the omicron variant and file for approval. They would then work to mass produce it by March.

On Friday, at a press conference, Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said that the agency was working on “pivoting the language” on COVID-19 vaccines, as she said that they wanted everyone to be up to date and explained it as follows: “That means if you recently got your second dose, you’re not eligible for a booster, you’re up to date.”

She added, “If you are eligible for a booster and you haven’t got it, you’re not up to date and you need to get your booster in order to be up to date.

Although the number of Covid cases are falling, the deaths have been crossing 2,000 from the past four days, according to data from Johns Hopkins University.

Image

Subscribe to get Latest News Updates

Latest News

You may like more
more

Advance Auto Parts Downgraded to Sell Amid Earnings Miss and Weak Outlook

CFRA analysts downgraded Advance Auto Parts (NYSE:AAP) from Hold...

Guggenheim Reiterates Buy Rating on Cabaletta Bio Amid Promising Data

Guggenheim analysts reaffirmed a Buy rating and a $23...

Goldman Sachs Initiates Neutral Coverage on Doximity, Highlights Balanced Growth Potential

Goldman Sachs analysts initiated coverage on Doximity (NYSE:DOCS) with...